Yuan Tian1, Jennifer L Guida2,3, Hela Koka2, Er-Ni Li1, Bin Zhu2, Hyuna Sung2,4, Ariane Chan5, Han Zhang2, Eric Tang2, Changyuan Guo1, Joseph Deng2, Nan Hu2, Ning Lu1, Gretchen L Gierach2, Jing Li1, Xiaohong R Yang2. 1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD, USA. 3. Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA. 4. Surveillance and Health Services Research, American Cancer Society, Atlanta, GA, USA. 5. Science and Technology, Volpara Health Technologies, Wellington, New Zealand.
Abstract
Background: Studies investigating associations between mammographic density (MD) and breast cancer subtypes have generated mixed results. We previously showed that having extremely dense breasts was associated with the human epidermal growth factor receptor-2 (HER2)-enriched subtype in Chinese breast cancer patients. Methods: In this study, we reevaluated the MD-subtype association in 1549 Chinese breast cancer patients, using VolparaDensity software to obtain quantitative MD measures. All statistical tests were 2-sided. Results: Compared with women with luminal A tumors, women with luminal B/HER2- (odds ratio [OR] = 1.20, 95% confidence interval [CI] = 1.04 to 1.38; P = .01), luminal B/HER2+ (OR = 1.22, 95% CI = 1.03 to 1.46; P = .03), and HER2-enriched tumors (OR = 1.30, 95% CI = 1.06 to 1.59; P = .01) had higher fibroglandular dense volume. These associations were stronger in patients with smaller tumors (<2 cm). In contrast, the triple-negative subtype was associated with lower nondense volume (OR = 0.82, 95% CI = 0.68 to 0.99; P = .04), and the association was only seen among older women (age 50 years or older). Conclusion: Although biological mechanisms remain to be investigated, the associations for the HER2-enriched and luminal B subtypes with increasing MD may partially explain the higher prevalence of luminal B and HER2+ breast cancers previously reported in Asian women. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
Background: Studies investigating associations between mammographic density (MD) and breast cancer subtypes have generated mixed results. We previously showed that having extremely dense breasts was associated with the human epidermal growth factor receptor-2 (HER2)-enriched subtype in Chinese breast cancer patients. Methods: In this study, we reevaluated the MD-subtype association in 1549 Chinese breast cancer patients, using VolparaDensity software to obtain quantitative MD measures. All statistical tests were 2-sided. Results: Compared with women with luminal A tumors, women with luminal B/HER2- (odds ratio [OR] = 1.20, 95% confidence interval [CI] = 1.04 to 1.38; P = .01), luminal B/HER2+ (OR = 1.22, 95% CI = 1.03 to 1.46; P = .03), and HER2-enriched tumors (OR = 1.30, 95% CI = 1.06 to 1.59; P = .01) had higher fibroglandular dense volume. These associations were stronger in patients with smaller tumors (<2 cm). In contrast, the triple-negative subtype was associated with lower nondense volume (OR = 0.82, 95% CI = 0.68 to 0.99; P = .04), and the association was only seen among older women (age 50 years or older). Conclusion: Although biological mechanisms remain to be investigated, the associations for the HER2-enriched and luminal B subtypes with increasing MD may partially explain the higher prevalence of luminal B and HER2+ breast cancers previously reported in Asian women. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
Authors: Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey Journal: J Natl Cancer Inst Date: 2012-07-05 Impact factor: 13.506
Authors: Brandy L Edwards; Kristen A Atkins; George J Stukenborg; Wendy M Novicoff; Krista N Larson; Wendy F Cohn; Jennifer A Harvey; Anneke T Schroen Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-07-11 Impact factor: 4.254
Authors: Johanna Holm; Louise Eriksson; Alexander Ploner; Mikael Eriksson; Mattias Rantalainen; Jingmei Li; Per Hall; Kamila Czene Journal: Cancer Res Date: 2017-05-16 Impact factor: 12.701
Authors: L Eriksson; P Hall; K Czene; I Dos Santos Silva; V McCormack; J Bergh; J Bjohle; A Ploner Journal: Br J Cancer Date: 2012-05-29 Impact factor: 7.640
Authors: G J Wengert; T H Helbich; R Woitek; P Kapetas; P Clauser; P A Baltzer; W-D Vogl; M Weber; A Meyer-Baese; Katja Pinker Journal: Eur Radiol Date: 2016-04-23 Impact factor: 5.315